1
|
Candido L, Alberghi C, Papa F, Ricapito I, Utili M, Venturini A, Zucchetti M. Experiments on the MHD Effect on the Drainage of a LiPb Channel and Supporting Numerical Computations with the Level Set Method. Fusion Science and Technology 2021. [DOI: 10.1080/15361055.2021.1893574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- L. Candido
- Politecnico di Torino, ESSENTIAL Group, Corso Duca degli Abruzzi 24, 10129 Torino, Italy
| | - C. Alberghi
- Politecnico di Torino, ESSENTIAL Group, Corso Duca degli Abruzzi 24, 10129 Torino, Italy
| | - F. Papa
- Sapienza University of Rome, Department of Astronautical, Electrical and Energy Engineering, Nuclear Section, Corso Vittorio Emanuele II 244, 00186 Roma, Italy
| | - I. Ricapito
- EU Commission Agency, Fusion for Energy (F4E), Aix-en-Provence, Provence-Alpes-Côte d’Azur, France
| | - M. Utili
- ENEA Centro Ricerche Brasimone, 40032 Camugnano (Bologna), Italy
| | - A. Venturini
- ENEA Centro Ricerche Brasimone, 40032 Camugnano (Bologna), Italy
| | - M. Zucchetti
- Politecnico di Torino, ESSENTIAL Group, Corso Duca degli Abruzzi 24, 10129 Torino, Italy
- Massachusetts Institute of Technology, Cambridge, Massachusetts
| |
Collapse
|
2
|
Meschini S, Zucchetti M, Pagliuca E. Development of an Advanced-Fuel Nuclear Fusion Experiment. Fusion Science and Technology 2021. [DOI: 10.1080/15361055.2021.1921461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- S. Meschini
- Politecnico di Torino, Department of Energy, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy
| | - M. Zucchetti
- Politecnico di Torino, Department of Energy, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy
- Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Enrico Pagliuca
- Politecnico di Torino, Department of Energy, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy
| |
Collapse
|
3
|
Bigini P, Gobbi M, Bonati M, Clavenna A, Zucchetti M, Garattini S, Pasut G. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat Nanotechnol 2021; 16:1169-1171. [PMID: 34732846 DOI: 10.1038/s41565-021-01001-3] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- P Bigini
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
| | - M Gobbi
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - M Bonati
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - A Clavenna
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - M Zucchetti
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - S Garattini
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - G Pasut
- Pharmaceutical and Pharmacological Sciences Department, University of Padova, Padua, Italy.
| |
Collapse
|
4
|
Candido L, Alberghi C, Antonelli A, Bassini S, Piccioni M, Storai S, Testoni R, Utili M, Zucchetti M. HyPer-QuarCh II: A laboratory-scale device for hydrogen isotopes permeation experiments. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112920] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Matteo C, Dovrtelova G, Di Clemente A, Frapolli R, Passoni A, Ceruti T, Marsella G, Cervo L, Zucchetti M. HPLC-MS/MS measurement of lidocaine in rat skin and plasma. Application to study the release from medicated plaster. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1138:121942. [PMID: 31918305 DOI: 10.1016/j.jchromb.2019.121942] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 10/18/2019] [Accepted: 12/16/2019] [Indexed: 11/17/2022]
Abstract
A simple, sensitive HPLC-MS/MS method was developed and validated for the determination of lidocaine in skin and plasma of rats. The methods were established and validated assessing lower limit of quantitation (LLOQ), linearity, intra and inter-day precision and accuracy, selectivity, recovery and matrix effect. Chromatography was done on a Gemini column embedded with C18 stationary phase (50 mm × 2.0 mm, 5 µm particle size), using a gradient with mobile phases consisting of 0.1% HCOOH in bidistilled water and 0.1% HCOOH in acetonitrile. The mass spectrometer worked with electrospray ionization in positive ion mode and selected reaction monitoring, using target ions m/z 235.10 for lidocaine and m/z 245.10 for lidocaine-d10, used as internal standard. RESULTS: The linearity of the method was in the ranges of lidocaine concentrations 10.0-200.0 ng/mL for skin homogenate (accuracy 94.1-105.5%; R2 ≥ 0.998) and 0.025-2 ng/mL for plasma (accuracy 96.2-104.8%; R2 ≥ 0.996). The intra- and inter-day precision and accuracy determined on three quality control samples (20, 75 and 170 ng/mL for skin and 0.075, 0.4 and 1.5 ng/mL for plasma) were ≤4.2% and 103.8-108.2% for skin and ≤12.4% and 95.5-101.4% for plasma. The LLOQ was 10 ng/mL in skin homogenate and 0.025 ng/mL in plasma. The applicability of the method was demonstrated by measuring lidocaine in skin and plasma after exposure to medicated patches containing 5% lidocaine.
Collapse
Affiliation(s)
- C Matteo
- Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - G Dovrtelova
- Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; Department of Pharmacology, Faculty of Medicine, RECETOX Centre, Faculty of Science, Masaryk University and International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic
| | - A Di Clemente
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - R Frapolli
- Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - A Passoni
- Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - T Ceruti
- Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - G Marsella
- Animal Care Unit, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - L Cervo
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - M Zucchetti
- Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
| |
Collapse
|
6
|
Dello Russo A, Della Rocca D, Gasperetti A, Casella M, Basso C, Bianchini L, Fassini G, Riva S, Moltrasio M, Ribatti V, Tundo F, Zucchetti M, Carbucicchio C, Natale A, Tondo C. P3682Myocardial structural abnormalities in nonischemic patients presenting with ventricular arrhythmias. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The diagnosis of concealed cardiomyopathies in patients with ventricular arrhythmias (VAs) is one of the major challenging issues faced by physicians.
Purpose
We aimed at reporting the cardiomyopathic substrate in patients with recurrent arrhythmias of ventricular origin.
Methods
Consecutive patients with unexplained VAs underwent a complete diagnostic work-out, including endomyocardial biopsy (EMB).
Results
Ninety-seven patients were enrolled (76.3% male, age 39.7±13.3 yrs). The presenting arrhythmic manifestation was aborted cardiac arrest in 30 (30.9%) patients, sustained ventricular tachycardia (VT) in 9 (9.3%), nonsustained VT in 15 (15.5%) and frequent premature ventricular complexes in 43 (44.3%). Overall, 350 biopsies were collected (3.6/patient). The incidence of procedure-related complications was 5.1% (n=5): 4 major complications (1 rupture of a tricuspid chorda tendinea w/o hemodynamic impairment, 1 dissection of right external iliac artery treated with stent, 1 thrombotic occlusion of left superficial femoral artery which required surgical treatment, 1 TIA) and 1 minor complication (groin hematoma) occurred. The final diagnosis was arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) (n=41; 42.3%), followed by myocarditis (n=20; 20.6%), dilated cardiomyopathy (n=6; 6.2%), cardiac sarcoidosis (n=6; 6.2%), and myocarditis in ARVD/C (n=5; 5.1%). Among the 25 patients whose final diagnosis was consistent with myocarditis, an acute stage of the disease was documented in 7 (7.2%), while a chronic myocarditis in 18 (18.5%). Additionally, according to medical history and diagnostic workout, in 2 of the 6 patients the dilated cardiomyopathy had a likely post-inflammatory etiology. Absence of myocardial abnormalities was documented in 15 (15.5%) patients: this group included 1 case of methadone-induced torsade de pointes. The remaining 4 (4.1%) patients were diagnosed with a cardiac hypertrophy (n=2, 2.1%, secondary to exercise or Fabry disease), a dilated mitochondrial cardiomyopathy (n=1, 1.0%), a dilated cardiomyopathy in Emery-Dreifuss muscular dystrophy (n=1; 1.0%).
Conclusion
In our series, approximately 45% of patients with unexplained VAs had a final diagnosis of ARVD/C.
Collapse
Affiliation(s)
| | - D Della Rocca
- St. David's Medical Center, Austin, United States of America
| | | | - M Casella
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - C Basso
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - L Bianchini
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Fassini
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - S Riva
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Moltrasio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Ribatti
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - F Tundo
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Zucchetti
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - A Natale
- St. Davids Medical Center, Texas Cardiac Arrhythmia Institute, Austin, United States of America
| | - C Tondo
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
7
|
Dello Russo A, Gasperetti A, Riva S, Dessanai M, Pizzamiglio F, Casella M, Chihade F, Catto V, Majocchi B, Zucchetti M, Ribatti V, Andreini D, Basso C, Zeppilli P, Tondo C. P307Magnetic resonance, electroanatomical mapping, and endomyocardial biopsy to solve the diagnostic and sport eligibility dilemma in a cohort of competitive athletes with ventricular arrhythmias. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Ventricular arrhythmias (VAs) are a frequent finding in agonist athletes (athl) at routine sport medicine visits. VAs impact on sport eligibility, their management, and the sudden arrhythmic death risk evaluation in athletes currently represents one of the greatest challenges across both the cardiology and sport medicine field.
Purpose
To describe how an advanced multi-methodical evaluation allowed diagnosis, risk stratification, targeted therapy and sport eligibility reassessment in a competitive athl cohort with ventricular arrhythmias and pathological findings at magnetic resonance (MR).
Methods
All consecutive competitive athl with denied sport eligibility due to ventricular arrhythmias that underwent an advanced invasive evaluation at our institute were enrolled.
A baseline and stress ECG, and late gadolinium enhanced evaluation (LGE) at MR were performed prior to invasive evaluation in all athl.
Invasive evaluation performed in all athl comprised of an electrophysiological study (EPS) to assess arrhythmic inducibility, an endo-cavitary electro-anatomical mapping (EAM), and a EAM and MR guided endo-myocardial biopsy (EMB). A defined diagnosis was postulated in all cases, specific therapeutic interventions were started and sport eligibility status reassessed after 6 months from discharge.
Results
Thirty-two competitive athl were enrolled in our study (32±6 y.o.; 77% male; 4±1 1h-training session/week); 26 (81%) athl practiced a mixed aerobic-anaerobic, 5 (16%) a pure-aerobic, while only 1 (3%) a pure anaerobic sport.
Arrhythmic presentation leading to sport eligibility revoke was: in 13 (40%) athl frequent (>2000/day) premature ventricular contractions (PVCs) at rest, in 2 (6%) PVCs during stress ECG, in 6 (18%) non-sustained ventricular tachycardia (VT), in 8 (25%) sustained VT, and in 3 (11%) ventricular fibrillation/cardiac arrest during sport practice.
MR alterations were described in all cases, and LGE at MR was found in 31 (87%) athl; a definite radiological diagnosis was obtained in 13 (40%) athl.
A normal myocardium at EMB was found only in 3 (8%) pts; in 15 (45%) a leukocyte infiltrate pattern compatible with myocarditis, in 11 (39%) fibro-fatty replacement, in 2 (5%) a mitochondrial disease and in 1 (3%) a sarcoidosis were proven, and diagnosis were consequently postulated.
EPS showed complex VAs inducibility in 8 (25%) cases, while a trans catheter ablation was performed in 10 (31%) athl. A total of 9 (28%) implantable cardioverter devices (ICDs) were implanted, for primary or secondary prevention.
According to invasive diagnostic findings and sport medicine guidelines, 8 (25%) athl had their sport eligibility statuts re-instated.
Conclusion
An invasive multi-methodical assessment allowed in all cases to reach a diagnosis and to start a targeted therapy in a cohort of competitive athl with VA and a pathological MR, granting in a significant (25%) percentage sport eligibility status re-instatement.
Collapse
Affiliation(s)
| | | | - S Riva
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Dessanai
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - M Casella
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - F Chihade
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Catto
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - B Majocchi
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Zucchetti
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - V Ribatti
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - D Andreini
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - C Basso
- University of Padova, Department of Cardiac, Thoracic and Vascular Sciences, Padua, Italy
| | - P Zeppilli
- Catholic University of the Sacred Heart, Sports Medicine Unit, Orthopedics, Aging and Rehabilitation Area, Rome, Italy
| | - C Tondo
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
8
|
Segantin S, Testoni R, Hartwig Z, Whyte D, Zucchetti M. Exploration of a Fast Pathway to Nuclear Fusion: Thermal Analysis and Cooling Design Considerations for the ARC Reactor. Fusion Science and Technology 2019. [DOI: 10.1080/15361055.2019.1629252] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- S. Segantin
- Politecnico di Torino, Dipartimento Energia, Italy
| | - R. Testoni
- Politecnico di Torino, Dipartimento Energia, Italy
| | - Z. Hartwig
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| | - D. Whyte
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| | - M. Zucchetti
- Politecnico di Torino, Dipartimento Energia, Italy
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| |
Collapse
|
9
|
Zucchetti M, Candido L, Hartwig Z, Po’ R, Segantin S, Testoni R, Whyte D. Neutronics Scoping Studies for Experimental Fusion Devices. Fusion Science and Technology 2019. [DOI: 10.1080/15361055.2019.1613141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- M. Zucchetti
- Politecnico di Torino, Department of Energy, Torino, Italy
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| | - L. Candido
- Politecnico di Torino, Department of Energy, Torino, Italy
| | - Z. Hartwig
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| | - R. Po’
- Eni SpA, Decarbonization & Environmental R&D Research & Technological Innovation, Novara, Italy
| | - S. Segantin
- Politecnico di Torino, Department of Energy, Torino, Italy
| | - R. Testoni
- Politecnico di Torino, Department of Energy, Torino, Italy
| | - D. Whyte
- Massachusetts Institute of Technology, Plasma Science and Fusion Center, Cambridge, Massachusetts
| |
Collapse
|
10
|
Zucchetti M, Chen Z, El-Guebaly L, Khripunov V, Kolbasov B, Maisonnier D, Someya Y, Subbotin M, Testoni R, Tobita K. Progress in International Radioactive Fusion Waste Studies. Fusion Science and Technology 2019. [DOI: 10.1080/15361055.2019.1602457] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
| | - Z. Chen
- Chinese Academy of Sciences, Institute of Nuclear Energy Safety Technology, Hefei, Anhui, China
| | - L. El-Guebaly
- University of Wisconsin–Madison, Fusion Technology Institute, Madison, Wisconsin
| | - V. Khripunov
- National Research Center “Kurchatov Institute,”, Moscow, Russian Federation
| | - B. Kolbasov
- National Research Center “Kurchatov Institute,”, Moscow, Russian Federation
| | - D. Maisonnier
- European Commission Research and Innovation, Brussels, Belgium
| | - Y. Someya
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho, Japan
| | - M. Subbotin
- National Research Center “Kurchatov Institute,”, Moscow, Russian Federation
| | | | - K. Tobita
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho, Japan
| |
Collapse
|
11
|
Affiliation(s)
- E.T. Cheng
- TSI Research, Inc. 225 Stevens Avenue Solana Beach, CA USA 92075
| | - P. Rocco
- European Commission - JRC Institute for Advanced Materials T.P.800, I-21020 Ispra (VA), Italy
| | - M. Zucchetti
- European Commission - JRC Institute for Advanced Materials T.P.800, I-21020 Ispra (VA), Italy
- Polytechnic of Torino, Energetics Department, C.so Duca degli Abruzzi 24, I-10129 Torino, Italy
| | - Y. Seki
- JAERI Mukouyama 801-1 Naka-machi, Naka-gun Ibaraki-ken 311-0102, Japan
| | - T. Tabara
- Sumitomo Atomic Energy Industries, Ltd., 2-10-14, Ryogoku, Sumidaku, Tokyo, 130 Japan
| |
Collapse
|
12
|
Zucchetti M, Riva M, Testoni R, Candido L, Coppi B. Neutron Generation in CANDOR, an Advanced-Fuel Fusion Experiment. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1347462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- M. Zucchetti
- Politecnico di Torino, DENERG, Italy
- Massachussetts Institute of Technology, Cambridge, Massachusetts
| | - M. Riva
- Politecnico di Torino, DENERG, Italy
- University of California, Los Angeles, California
| | | | | | - B. Coppi
- Massachussetts Institute of Technology, Cambridge, Massachusetts
| |
Collapse
|
13
|
Zucchetti M, Chang Z, El-Guebaly L, Han JH, Kolbasov B, Khripunov V, Riva M, Someya Y, Testoni R, Tobita K. Radioactive Waste Studies in the Frame of the IEA Cooperative Program on the Environmental, Safety, and Economic Aspects of Fusion Power. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1350474] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - Z. Chang
- Chinese Academy of Sciences, Institute of Nuclear Energy Safety Technology, Hefei, Anhui, China
| | | | | | - B. Kolbasov
- National Research Center “Kurchatov Institute,” Moscow, Russia
| | - V. Khripunov
- National Research Center “Kurchatov Institute,” Moscow, Russia
| | - M. Riva
- Politecnico di Torino, Torino, Italy
- University of California at Los Angeles, Los Angeles, California
| | - Y. Someya
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho, Japan
| | | | - K. Tobita
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho, Japan
| |
Collapse
|
14
|
Zucchetti M, Ciampichetti A. Safety and Radioactive Waste Management Aspects of the Ignitor Fusion Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst56-814] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Zucchetti
- DENER, Politecnico di Torino Corso Duca degli Abruzzi, 24 – 10129 Torino (Italy)
| | - A. Ciampichetti
- DENER, Politecnico di Torino Corso Duca degli Abruzzi, 24 – 10129 Torino (Italy)
| |
Collapse
|
15
|
Zucchetti M, Di Pace L, El-Guebaly L, Kolbasov BN, Massaut V, Pampin R, Wilson P. The Back-End of Fusion Materials Cycle: Recycling, Clearance and Disposal. Fusion Science and Technology 2017. [DOI: 10.13182/fst09-a9004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Zucchetti
- EURATOM/ENEA Fusion Association, Politecnico di Torino, Torino, Italy
| | - L. Di Pace
- EURATOM/ENEA Fusion Association, ENEA CRE Frascati, Rome, Italy
| | | | | | | | - R. Pampin
- EURATOM/UKAEA Fusion Association, Culham Science Centre, Abingdon, U.K
| | - P. Wilson
- University of Wisconsin-Madison, Madison, WI, U.S.A
| |
Collapse
|
16
|
Ricapito I, Ciampichetti A, Benamati G, Zucchetti M. Tritium Extraction Systems for the European HCLL/HCPB TBMs. Fusion Science and Technology 2017. [DOI: 10.13182/fst08-a1775] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- I. Ricapito
- ENEA FPN-FISING, CR Brasimone, 40033 Camugnano (Bo), Italy
| | | | - G. Benamati
- ENEA FPN-FISING, CR Brasimone, 40033 Camugnano (Bo), Italy
| | - M. Zucchetti
- DENER, Politecnico di Torino, 10129 Torino, Italy
| |
Collapse
|
17
|
Zucchetti M, Pace LD, El-Guebaly L, Kolbasov BN, Massaut V, Pampin R, Wilson P. The Back End of the Fusion Materials Cycle. Fusion Science and Technology 2017. [DOI: 10.13182/fst09-12] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Zucchetti
- EURATOM/ENEA Fusion Association, Politecnico di Torino, Torino, Italy
| | - L. Di Pace
- EURATOM/ENEA Fusion Association, ENEA CR Frascati, Rome, Italy
| | | | | | | | - R. Pampin
- EURATOM0UKAEA Fusion Association, Culham Science Centre, Abingdon, United Kingdom
| | - P. Wilson
- University of Wisconsin-Madison, Madison, Wisconsin
| |
Collapse
|
18
|
Zucchetti M, Bombarda F, Coppi B, Hartwig ZS. Compact Tokamak Neutron Sources as a First Step Towards Hybrid Fission-Fusion Reactors. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a19141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Zucchetti
- Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino, Italy
- Massachusetts Institute of Technology, MIT, 77 Mass Ave, Cambridge (MA), USA
| | | | - B. Coppi
- Massachusetts Institute of Technology, MIT, 77 Mass Ave, Cambridge (MA), USA
| | - Z. S. Hartwig
- Massachusetts Institute of Technology, MIT, 77 Mass Ave, Cambridge (MA), USA
| |
Collapse
|
19
|
Affiliation(s)
| | | | - A. Ying
- University of California Los Angeles, Los Angeles
| | - M. Abdou
- University of California Los Angeles, Los Angeles
| |
Collapse
|
20
|
Franza F, Ciampichetti A, Ricapito I, Zucchetti M. Sensitivity Study for Tritium Permeation in Helium-Cooled Lead-Lithium DEMO Blanket with the FUS-TPC Code. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a19162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Franza
- Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, 76344, Germany
| | | | | | | |
Collapse
|
21
|
Affiliation(s)
- L. El-Guebaly
- University of Wisconsin, 1500 Engineering Dr., Madison, WI 53706, USA,
| | - M. Zucchetti
- Politecnico di Torino, Corso Duca degli Abruzzi 24 - 10129 Torino, Italy,
| |
Collapse
|
22
|
Affiliation(s)
- M. Zucchetti
- Politecnico di Torino, Corso Duca degli Abruzzi 24 - 10129 Torino, Italy
- MIT – Massachusetts Institute of Technology, Cambridge (MA), US
| | - M. Riva
- Politecnico di Torino, Corso Duca degli Abruzzi 24 - 10129 Torino, Italy
| | - B. Coppi
- MIT – Massachusetts Institute of Technology, Cambridge (MA), US
| |
Collapse
|
23
|
Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J. Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Ann Oncol 2015; 26:445. [PMID: 32590894 DOI: 10.1093/annonc/mdu547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J-C Soria
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France
| | - F DeBraud
- European Institute of Oncology, Milan, Italy
| | - R Bahleda
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France
| | - B Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - F Andre
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France
| | - R Dienstmann
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle
| | - A Delmonte
- European Institute of Oncology, Milan, Italy
| | - R Cereda
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy
| | - J Isaacson
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy
| | - J Litten
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy
| | - A Allen
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy
| | - F Dubois
- Institut de Recherche International Servier, Suresnes, France
| | - C Saba
- Institut de Recherche International Servier, Suresnes, France
| | - R Robert
- Institut de Recherche International Servier, Suresnes, France
| | - M D'Incalci
- Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
| | - M Zucchetti
- Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
| | - M G Camboni
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder, USA; Clovis Oncology, Inc., Milan, Italy
| | - J Tabernero
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
24
|
Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dientsmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014; 25:2244-2251. [PMID: 25193991 DOI: 10.1093/annonc/mdu390] [Citation(s) in RCA: 141] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor receptor types α and β (PGFRα/β), which are essential kinases for tumor growth, survival, migration, and angiogenesis. Several tumor types, including breast carcinoma, demonstrate amplification of fibroblast growth factor (FGF)-related genes. There are no approved drugs for molecularly defined FGF-aberrant (FGFR1- or FGF3/4/19-amplified) tumors. METHODS This open-label phase I/IIa study involved a dose-escalation phase to determine maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics of lucitanib in patients with advanced solid tumors, followed by a dose-expansion phase to obtain preliminary evidence of efficacy in patients who could potentially benefit from treatment (i.e. with tumors harboring FGF-aberrant pathway or considered angiogenesis-sensitive). RESULTS Doses from 5 to 30 mg were evaluated with dose-limiting toxic effects dominated by vascular endothelial growth factor (VEGF) inhibition-related toxic effects at the 30 mg dose level (one case of grade 4 depressed level of consciousness and two cases of grade 3 thrombotic microangiopathy). The most common adverse events (all grades, all cohorts) were hypertension (91%), asthenia (42%), and proteinuria (57%). Exposure increased with dose and t½ was 31-40 h, suitable for once daily administration. Seventy-six patients were included. All but one had stage IV; 42% had >3 lines of previous chemotherapy. Sixty-four patients were assessable for response; 58 had measurable disease. Clinical activity was observed at all doses tested with durable Response Evaluation Criteria In Solid Tumors (RECIST) partial responses in a variety of tumor types. In the angiogenesis-sensitive group, objective RECIST response rate (complete response + partial response) was 26% (7 of 27) and progression-free survival (PFS) was 25 weeks. In assessable FGF-aberrant breast cancer patients, 50% (6 of 12) achieved RECIST partial response with a median PFS of 40.4 weeks for all treated patients. CONCLUSION Lucitanib has promising efficacy and a manageable side-effect profile. The spectrum of activity observed demonstrates clinical benefit in both FGF-aberrant and angiogenesis-sensitive populations. A comprehensive phase II program is planned.
Collapse
Affiliation(s)
- J-C Soria
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France.
| | - F DeBraud
- European Institute of Oncology, Milan, Italy
| | - R Bahleda
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France
| | - B Adamo
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - F Andre
- Department of Drug Development, Gustave-Roussy Cancer Campus, Villejuif, France
| | - R Dientsmann
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle
| | - A Delmonte
- European Institute of Oncology, Milan, Italy
| | - R Cereda
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder,USA; Clovis Oncology, Inc., Milan, Italy
| | - J Isaacson
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder,USA; Clovis Oncology, Inc., Milan, Italy
| | - J Litten
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder,USA; Clovis Oncology, Inc., Milan, Italy
| | - A Allen
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder,USA; Clovis Oncology, Inc., Milan, Italy
| | - F Dubois
- Institut de Recherche International Servier, Suresnes, France
| | - C Saba
- Institut de Recherche International Servier, Suresnes, France
| | - R Robert
- Institut de Recherche International Servier, Suresnes, France
| | - M D'Incalci
- Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
| | - M Zucchetti
- Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, Milan, Italy
| | - M G Camboni
- Clovis Oncology, Inc., San Francisco; Clovis Oncology, Inc., Boulder,USA; Clovis Oncology, Inc., Milan, Italy
| | - J Tabernero
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
25
|
Cesca M, Morosi L, Zucchetti M, Frapolli R, Giordano S, Richter P, Dirsch O, Bernd A, Giavazzi R. 671: Inhibition of angiogenesis promotes a homogeneous intra-tumor distribution of chemotherapy associated with better antitumor response. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50591-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Franza F, Boccaccini L, Ciampichetti A, Zucchetti M. Tritium transport analysis in HCPB DEMO blanket with the FUS-TPC code. Fusion Engineering and Design 2013. [DOI: 10.1016/j.fusengdes.2013.05.045] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Zucchetti M, Di Pace L, El-Guebaly L, Han JH, Kolbasov B, Massaut V, Someya Y, Tobita K, Desecures M. Recent advances in fusion radioactive material studies. Fusion Engineering and Design 2013. [DOI: 10.1016/j.fusengdes.2013.02.050] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Bombarda F, Coppi B, Franza F, Hartwig ZS, Ramogida G, Zucchetti M. A High Field Tokamak Neutron Source Facility. Fusion Science and Technology 2012. [DOI: 10.13182/fst12-a13403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | - B. Coppi
- Massachusetts Institute of Technology, MIT, Cambridge (MA), USA
| | | | - Z. S. Hartwig
- Massachusetts Institute of Technology, MIT, Cambridge (MA), USA
| | | | - M. Zucchetti
- Massachusetts Institute of Technology, MIT, Cambridge (MA), USA
- Politecnico di Torino, Italy,
| |
Collapse
|
29
|
Affiliation(s)
- M. Zucchetti
- Politecnico di Torino, Italy,
- Massachusetts Institute of Technology, MIT, Cambridge (MA), USA
| | | | - B. Coppi
- Massachusetts Institute of Technology, MIT, Cambridge (MA), USA
| |
Collapse
|
30
|
Bombarda F, Coppi B, Hartwig Z, Sassi M, Zucchetti M. Compact tokamaks as convenient neutron sources for fusion reactors materials testing. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2011.04.059] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Zucchetti M, Guerrini L, Poitevin Y, Ricapito I, Zmitko M. Radioactive Safety Estimates for ITER TBM Systems. Fusion Science and Technology 2011. [DOI: 10.13182/fst11-a12477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Zucchetti
- EURATOM/ENEA Fusion Association, Politecnico di Torino, Torino, Italy
| | - L. Guerrini
- Fusion for Energy, ITER Department, Test Blanket Modules Group, Barcelona, Spain
| | - Y. Poitevin
- Fusion for Energy, ITER Department, Test Blanket Modules Group, Barcelona, Spain
| | - I. Ricapito
- Fusion for Energy, ITER Department, Test Blanket Modules Group, Barcelona, Spain
| | - M. Zmitko
- Fusion for Energy, ITER Department, Test Blanket Modules Group, Barcelona, Spain
| |
Collapse
|
32
|
Deshmukh A, Sharma SS, Gobal FG, Singla SS, Hebbar PH, Paydak HP, Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, Yoshida K, Aonuma K, Shavadia J, Otieno H, Yonga G, Jinah A, Qvist JF, Soerensen PH, Dixen U, Ramirez-Marrero MA, Perez-Villardon B, Gaitan-Roman D, Jimenez-Navarro M, Delgado-Prieto JL, De Teresa-Galvan E, De Mora-Martin M, Deshmukh A, Hebbar PB, Wei WX, Gobal FG, Singla SS, Sharma SS, Paydak HP, Bardari S, Zecchin M, Salame' R, Vitali Serdoz L, Di Lenarda A, Guerrini N, Barbati G, Sinagra G, Hanazawa K, Kaitani K, Nakagawa Y, Lenaerts I, Driesen R, Hermida N, Heidbuchel H, Janssens S, Balligand JL, Sipido KR, Willems R, Sehra R, Krummen D, Briggs C, Narayan S, Tanaka Y, Hirao K, Nakamura T, Inaba O, Yagishita A, Higuchi K, Hachiya H, Isobe M, Kallergis E, Kanoupakis EM, Mavrakis HE, Goudis CA, Maliaraki NE, Vardas PE, Sehra R, Krummen D, Briggs C, Narayan S, Kiuchi K, Piorkowski C, Kircher S, Gaspar T, Watanabe N, Bollmann A, Hindricks G, Wauters K, Grosse A, Raffa S, Brunelli M, Geller JC, Maggioni AP, Gonzini L, Gussoni G, Vescovo G, Gulizia M, Pirelli S, Mathieu G, Di Pasquale G, Zecchin M, Bardari S, Vitali Serdoz L, Salame R, Buja G, Rovai N, Gargaro A, Sperzel J, Knops RE, Meine M, Speca G, Santini L, Haarbo J, Dubin K, Di Lenarda A, Carlson M, Garcia Quintana A, Mendoza-Lemes H, Garcia Perez L, Led Ramos S, Caballero Dorta E, Matinez De Espronceda M, Piro Mastracchio V, Serrano Arriezu L, Sciarra L, Barbati G, Marziali M, Marras E, Rebecchi M, Allocca G, Lioy E, Delise P, Calo' L, Santobuono VE, Iacoviello M, Nacci F, Magnani S, Luzzi G, Puzzovivo A, Memeo M, Quadrini F, Favale S, Trucco ME, Arce M, Palazzolo J, Uribe W, Baranchuk A, Sinagra G, Femenia F, Maggi R, Furukawa T, Croci F, Solano A, Brignole M, Lebreiro A, Sousa A, Correia AS, Lourenco P, Sakamoto T, Oliveira S, Paiva M, Freitas J, Maciel MJ, Linker N, Rieger G, Garutti C, Edvardsson N, Salguero Bodes R, De Riva Silva M, Kumagai K, Fontenla Cerezuela A, Lopez Gil M, Mejia Martinez E, Jurado Roman A, Garcia Alvarez S, Arribas Ynsaurriaga F, Petix NR, Del Rosso A, Guarnaccia V, Zipoli A, Fuke E, Rabajoli F, Foglia Manzillo G, Tolardo C, Checchinato C, Chiaravallotti S, Santarone M, Spinnler MT, Podoleanu C, Maggi R, Brignole M, Nishiuchi S, Frigy A, Dobreanu D, Ginghina C, Carasca E, Hayashi T, Miki Y, Naito S, Oshima S, Hof IE, Vonken E, Velthuis BK, Meine M, Hauer RNW, Loh KP, Na JO, Choi CU, Kim EJ, Rha SW, Park CG, Seo HS, Oh DJ, Lim HE, Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Kuroki K, Machino T, Yoshida K, Aonuma K, Wichterle D, Bulkova V, Fiala M, Chovancik J, Simek J, Peichl P, Cihak R, Kautzner J, Glick A, Viskin S, Belhassen B, Navarrete A, Conte F, Ishti A, Sai D, Moran M, Chitovova Z, Ahmed H, Mares K, Skoda J, Sediva L, Petru J, Reddy VY, Neuzil P, Schmidt M, Dorwarth U, Leber A, Wankerl M, Krieg J, Straube F, Reif S, Hoffmann E, Mikhaylov E, Tikhonenko V, Lebedev D, Lim HE, Shin SY, Yong HS, Choi CU, Choi JI, Kim SH, Kim EJ, Na JO, Matsuo S, Yamane T, Hioki M, Ito K, Narui R, Date T, Sugimoto K, Yoshimura M, Rolf S, Piorkowski C, Gaspar T, Sommer P, Hindricks G, Batalov R, Popov S, Antonchenko I, Suslova T, Fichtner S, Czudnochowsky U, Estner HL, Ammar S, Reents T, Jilek C, Hessling G, Deisenhofer I, Pokushalov E, Romanov A, Corbucci G, Artemenko S, Losik D, Shabanov V, Turov A, Elesin D, Mikhaylov E, Abramov M, Lebedev D, Piorkowski C, Sanders P, Jais P, Roberts-Thomson K, Hindricks G, Fukumoto K, Takatsuki S, Kimura T, Nishiyama N, Aizawa Y, Sato T, Miyoshi S, Fukuda K, Roux Y, Tenkorang J, Carroz P, Schlaepfer J, Pascale P, Forclaz A, Fromer M, Pruvot E, Fiala M, Wichterle D, Bulkova V, Sknouril L, Nevralova R, Chovancik J, Dorda M, Januska J, Brunelli M, Grosse A, Santi R, Wauters K, Geller C, Kumagai K, Nakamura K, Hayashi T, Kasseno K, Naito S, Sakamoto T, Oshima S, Taniguchi K, Wutzler A, Rolf S, Huemer M, Parwani A, Boldt LH, Blaschke D, Dietz R, Haverkamp W, Coutu B, Malanuk R, Ait Said M, Vicentini A, Schade S, Ando K, Rousseauplasse A, Deering T, Picarra BC, Santos AR, Dionisio P, Semedo P, Matos R, Leitao M, Jacinto A, Trinca M, Wan C, Glad J, Szymkiewicz S, Habibovic M, Versteeg H, Pelle AJM, Theuns DAMJ, Jordaens L, Pedersen SS, Pakarinen S, Toivonen L, Reif S, Schade S, Taggeselle J, Frey A, Birkenhagen A, Kohler S, Schmidt M, Maier SKG, Lobitz N, Paule S, Becher J, Mustafa G, Ibrahim A, King G, Foley B, Wilkoff B, Freedman R, Hayes D, Kalbfleisch S, Kutalek S, Schaerf R, Fazal IA, Tynan M, Plummer CJ, Mccomb JM, Oto A, Aytemir K, Yorgun H, Canpolat U, Kaya EB, Tokgozoglu L, Kabakci G, Ozkutlu H, Greenberg S, Hamati F, Styperek R, Alonso J, Peress D, Bolanos O, Augostini R, Pelini M, Zhang S, Stoycos S, Witsaman S, Mowrey K, Bremer J, Oza A, Ciconte G, Mazzone P, Paglino G, Marzi A, Vergara P, Sora N, Gulletta S, Della Bella P, Nagashima M, Goya M, Soga Y, Hiroshima K, Andou K, Hayashi K, An Y, Nobuyoshi M, Kutarski A, Malecka B, Pietura R, Osmancik P, Herman D, Stros P, Kocka V, Tousek P, Linkova H, Bortnik M, Occhetta E, Dell'era G, Degiovanni A, Plebani L, Marino PN, Gorev MV, Alimov DG, Raju P, Kully S, Ugni S, Furniss S, Lloyd G, Patel NR, Richards MW, Warren CE, Anderson MH, Hero M, Rey JL, Ouali S, Azzez S, Kacem S, Hammas S, Ben Salem H, Neffeti E, Remedi F, Boughzela E, Kronborg MB, Mortensen PT, Poulsen SH, Nielsen JC, Simantirakis EN, Kontaraki JE, Arkolaki EG, Chrysostomakis SI, Nyktari EG, Patrianakos AP, Vardas PE, Funck RC, Harink C, Mueller HH, Koelsch S, Maisch B, Bortnik M, Occhetta E, Dell'era G, Degiovanni A, Bolzani V, Marino PN, Costandi P, Shehada RE, Butala N, Coppola B, Taborsky M, Heinc P, Fedorco M, Doupal V, Di Cori A, Zucchelli G, Soldati E, Segreti L, De Lucia R, Viani S, Paperini L, Bongiorni MG, Gutleben KJ, Kranig W, Barr C, Morgenstern MM, Simon M, Dalal YH, Landolina M, Pierantozzi A, Agricola T, Lunati M, Pisano' E, Lonardi G, Bardelli G, Zucchi G, Thibault B, Dubuc M, Karst E, Ryu K, Paiement P, Carlson MD, Farazi T, Alhous H, Mont L, Porres JM, Alzueta J, Beiras X, Fernandez-Lozano I, Macias A, Ruiz R, Brugada J, Viani SM, Segreti L, Di Cori A, Zucchelli G, Paperini L, Soldati E, De Lucia R, Bongiorni MG, Seifert M, Schau T, Moeller V, Meyhoefer J, Butter C, Ganiere V, Niculescu V, Domenichini G, Stettler C, Defaye P, Burri H, Stockburger M, De Teresa E, Lamas G, Desaga M, Koenig C, Cobo E, Navarro X, Wiegand U, Blich M, Carasso S, Suleiman M, Marai I, Gepstein L, Boulos M, Sasov M, Liska B, Margitfalvi P, Malacky T, Svetlosak M, Goncalvesova E, Hatala R, Takaya Y, Noda T, Yamada Y, Okamura H, Satomi K, Shimizu W, Aihara N, Kamakura S, Proclemer A, Boveda S, Oswald H, Scipione P, Rousseauplasse A, Da Costa A, Brzozowski W, Tomaszewski A, Kutarski A, Wysokinski A, Arbelo E, Tamborero D, Vidal B, Tolosana JM, Sitges M, Matas M, Brugada J, Mont L, Botto GL, Dicandia CD, Mantica M, La Rosa C, D' Onofrio A, Molon G, Raciti G, Verlato R, Foley PWX, Chalil S, Ratib K, Smith REA, Printzen F, Auricchio A, Leyva F, Abu Sham'a R, Buber J, Luria D, Kuperstein R, Feinberg M, Granit H, Eldar M, Glikson M, Osmancik P, Herman D, Stros P, Vondrak K, Abu Sham'a R, Nof E, Kuperstein R, Carasso S, Feinberg M, Lipchenca I, Eldar M, Glikson M, Vatasescu RG, Iorgulescu C, Caldararu C, Vasile A, Bogdan S, Constantinescu D, Dorobantu M, Sakaguchi H, Miyazaki A, Yamamoto T, Fujimoto K, Ono S, Ohuchi H, Martinelli M, Martins S, Molina R, Siqueira S, Nishioka SAD, Peixoto GL, Alkmim-Teixeira R, Costa R, Versteeg H, Meine MM, Tuinenburg AE, Doevendans PA, Denollet J, Pedersen SS, Goscinska-Bis K, Zupan I, Van Der H, Anselme F, Hartog H, Block M, Borri A, Padeletti L, Toniolo M, Zanotto G, Rossi A, Raytcheva E, Tomasi L, Vassanelli C, Fernandez Lozano I, Mitroi C, Toquero Ramos J, Castro Urda V, Monivas Palomero V, Corona Figueroa A, Ruiz Bautista L, Alonso Pulpon L, Jadidi AS, Sacher F, Shah AS, Scherr D, Derval N, Hocini M, Haissaguerre M, Jais P, Castrejon Castrejon S, Largo-Aramburu C, Sachar J, Gang E, Estrada A, Doiny D, De Miguel E, Merino JL, Vergara P, Trevisi N, Ricco A, Petracca F, Baratto F, Bisceglie A, Maccabelli G, Della Bella P, El-Damaty A, Sapp J, Warren J, Macinnis P, Horacek M, Dinov B, Schoenbauer R, Piorkowski C, Bollmann A, Sommer P, Braunschweig F, Hindricks G, Arya A, Andreu D, Berruezo A, Ortiz JT, Silva E, Mont L, De Caralt TM, Fernandez-Armenta J, Brugada J, Castrejon Castrejon S, Estrada A, Doiny D, Perez-Silva A, Ortega M, Lopez-Sendon JL, Merino JL, Regoli F, Faletra F, Nucifora G, Pasotti E, Moccetti T, Klersy C, Auricchio A, Casella M, Dello Russo A, Moltrasio M, Zucchetti M, Fassini G, Di Biase L, Natale A, Tondo C, Sakamoto T, Kumagai K, Matsuhashi N, Nishiuchi S, Fuke E, Hayashi T, Naito S, Oshima S, Weig HJ, Kerst G, Weretk S, Seizer P, Gawaz MP, Schreieck J, Sarquella-Brugada G, Prada F, Brugada J, Reents T, Ammar S, Fichtner S, Salling CM, Jilek C, Kolb C, Hessling G, Deisenhofer I, Pytkowski M, Maciag A, Farkowski M, Jankowska A, Kowalik I, Kraska A, Szwed H, Maury P, Hocini M, Sacher F, Duparc A, Mondoly P, Rollin A, Jais P, Haissaguerre M, Pap R, Kohari M, Bencsik G, Makai A, Saghy L, Forster T, Ebrille E, Scaglione M, Raimondo C, Caponi D, Di Donna P, Blandino A, Delcre SDL, Gaita F, Roca Luque I, Dos LDS, Rivas NRG, Pijuan APD, Perez J, Casaldaliga J, Garcia-Dorado DGD, Moya AMM, Sato H, Yagi T, Yambe T, Streitner F, Dietrich C, Mahl E, Schoene N, Veltmann C, Borggrefe M, Kuschyk J, Sadarmin PP, Wong KCK, Rajappan K, Bashir Y, Betts TR, Svetlosak M, Leclercq C, Martins R, Hatala R, Daubert JC, Mabo P, Koide M, Hamano G, Taniguchi T, Yamato M, Sasaki N, Hirooka K, Ikeda Y, Yasumura Y, Dichtl W, Wolber T, Paoli U, Bruellmann S, Berger T, Stuehlinger M, Duru F, Hintringer F, Kanoupakis E, Mavrakis H, Kallergis E, Koutalas E, Saloustros I, Goudis C, Chlouverakis G, Vardas P, Herre JM, Saeed M, Saberi L, Neuman S, An Y, Ando K, Goya M, Nagashima M, Yamaji K, Soga Y, Iwabuchi M, Nobuyoshi M, Baranchuk A, Femenia F, Miranda Hermosilla R, Lopez Diez JC, Serra JL, Valentino M, Retyk E, Galizio N, Kwasniewski W, Filipecki A, Orszulak W, Urbanczyk-Swic D, Trusz - Gluza M, Piot O, Degand B, Da Costa A, Donofrio A, Scanu P, Quesada A, Rousseauplasse A, Padeletti L, Kloppe A, Mijic D, Bogossian H, Zarse M, Lemke B, Tyler J, Comfort G, Kalbfleisch S, Deering TF, Epstein AE, Greenberg SMG, Goldman DS, Rhude J, Majewski JP, Lelakowski J, Tomala I, Santos CM, Miranda RS, Sousa PJ, Cavaco DM, Adragao PP, Knops RE, Wilde AA, Da Costa A, Belhameche M, Hermida JS, Dovellini E, Frohlig G, Siot P, Degand B, Duray GZ, Israel CW, Brachmann J, Seidl KH, Foresti M, Birkenhauer F, Hohnloser SH, Ferreira C, Mateus P, Ribeiro H, Carvalho S, Ferreira A, Moreira J, Kadro W, Rahim H, Turkmani M, Abu Lebdeh M, Altabban A, Raimondo C, Scaglione M, Ebrille E, Caponi D, Di Donna P, Cerrato N, Delcre SDL, Gaita F, Rivera S, Scazzuso F, Albina G, Klein A, Laino R, Sammartino V, Giniger A, Kvantaliani T, Akhvlediani M, Namdar M, Steffel J, Jetzer S, Bayrak F, Chierchia GB, Jenni R, Duru F, Brugada P, Bakos Z, Medvedev M MM, Jonas Carlsson JC, Fredrik Holmqvist FH, Pyotr Platonov PP, Nurbaev T, Pirnazarov M, Nikishin A, Aagaard P, Sahlen A, Bergfeldt L, Braunschweig F, Simeonidou E, Kastellanos S, Varounis C, Michalakeas C, Koniari C, Nikolopoulou A, Anastasiou-Nana M, Furukawa Y, Yamada T, Morita T, Tanaka K, Iwasaki Y, Kawasaki M, Kuramoto Y, Fukunami M, Blanche C, Tran N, Rigamonti F, Zimmermann M, Okisheva E, Tsaregorodtsev D, Sulimov V, Novikova D, Popkova T, Udachkina E, Korsakova Y, Volkov A, Novikov A, Alexandrova E, Nasonov E, Arsenos P, Gatzoulis K, Manis G, Dilaveris P, Gialernios T, Kartsagoulis E, Asimakopoulos S, Stefanadis C, Marocolo M, Barbosa Neto O, Carvalho AC, Marques Neto SR, Mota GR, Barbosa PRB, Fernandez-Fernandez A, Manzano Fernandez S, Pastor-Perez FJ, Barquero-Perez O, Goya-Esteban R, Salar M, Rojo-Alvarez JL, Garcia-Alberola A, Takigawa M, Kawamura M, Aiba T, Kamakura S, Sakaguchi T, Itoh H, Horie M, Shimizu W, Miyazaki A, Sakaguchi H, Yamamoto T, Igarashi T, Negishi J, Toyota N, Ohuchi H, Yamada O, Arsenos P, Gatzoulis K, Manis G, Dilaveris P, Gialernios T, Papavasileiou M, Asimakopoulos S, Stefanadis C, Cabrera Bueno F, Molina Mora MJ, Alzueta Rodriguez J, Barrera Cordero A, De Teresa Galvan E, Revishvili AS, Dzhordzhikiya T, Sopov O, Simonyan G, Lyadzhina O, Fetisova E, Kalinin V, Balt JC, Steggerda RC, Boersma LVA, Wijffels MCEF, Wever EFD, Ten Berg JM, Ricci RP, Morichelli L, D'onofrio A, Zanotto G, Vaccari D, Calo' L. Poster Session 1. Europace 2011. [DOI: 10.1093/europace/eur220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Soria J, De Braud FG, Cereda R, Bahleda R, Delmonte A, Angevin E, Varga A, Noberasco C, Dall'O' E, Lassau N, Dromain C, Bellomi M, Farace F, Bertolini F, Zucchetti M, Marsoni S, Camboni MG. First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Landoni G, Augoustides JG, Guarracino F, Santini F, Ponschab M, Pasero D, Rodseth RN, Biondi-Zoccai G, Silvay G, Salvi L, Camporesi E, Comis M, Conte M, Bevilacqua S, Cabrini L, Cariello C, Caramelli F, De Santis V, Del Sarto P, Dini D, Forti A, Galdieri N, Giordano G, Gottin L, Greco M, Maglioni E, Mantovani L, Manzato A, Meli M, Paternoster G, Pittarello D, Rana KN, Ruggeri L, Salandin V, Sangalli F, Zambon M, Zucchetti M, Bignami E, Alfieri O, Zangrillo A. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference. Acta Anaesthesiol Scand 2011; 55:259-66. [PMID: 21288207 DOI: 10.1111/j.1399-6576.2010.02381.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
There is no consensus on which drugs/techniques/strategies can affect mortality in the perioperative period of cardiac surgery. With the aim of identifying these measures, and suggesting measures for prioritized future investigation we performed the first International Consensus Conference on this topic. The consensus was a continuous international internet-based process with a final meeting on 28 June 2010 in Milan at the Vita-Salute University. Participants included 340 cardiac anesthesiologists, cardiac surgeons, and cardiologists from 65 countries all over the world. A comprehensive literature review was performed to identify topics that subsequently generated position statements for discussion, voting, and ranking. Of the 17 major topics with a documented mortality effect, seven were subsequently excluded after further evaluation due to concerns about clinical applicability and/or study methodology. The following topics are documented as reducing mortality: administration of insulin, levosimendan, volatile anesthetics, statins, chronic β-blockade, early aspirin therapy, the use of pre-operative intra-aortic balloon counterpulsation, and referral to high-volume centers. The following are documented as increasing mortality: administration of aprotinin and aged red blood cell transfusion. These interventions were classified according to the level of evidence and effect on mortality and a position statement was generated. This International Consensus Conference has identified the non-surgical interventions that merit urgent study to achieve further reductions in mortality after cardiac surgery: insulin, intra-aortic balloon counterpulsation, levosimendan, volatile anesthetics, statins, chronic β-blockade, early aspirin therapy, and referral to high-volume centers. The use of aprotinin and aged red blood cells may result in increased mortality.
Collapse
Affiliation(s)
- G Landoni
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Canta A, Chiorazzi A, Carozzi V, Meregalli C, Oggioni N, Sala B, Crippa L, Avezza F, Forestieri D, Rotella G, Zucchetti M, Cavaletti G. In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™). Cancer Chemother Pharmacol 2011; 68:1001-8. [PMID: 21327681 DOI: 10.1007/s00280-011-1574-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Accepted: 01/26/2011] [Indexed: 12/15/2022]
Abstract
PURPOSE Cisplatin is one of the most effective cytotoxic agents in the treatment of solid malignancies, but its use is limited by several side effects. Among them, peripheral neurotoxicity can be dose limiting. A liposomal formulation of cisplatin, Lipoplatin™, was developed to reduce the systemic toxicity of cisplatin but without preventing its efficacy. The aim of this study was to use an animal model to establish, through a multimodal approach, whether chronic treatment with two different schedules of Lipoplatin™, selected within the range of its anticancer effective dose, is less neurotoxic than cisplatin administration. METHODS Female Wistar rats were treated intraperitoneally with cisplatin at a dose of 4 mg/kg or with Lipoplatin™ at doses delivering 12 or 24 mg/kg of cisplatin once weekly for 4 weeks. General toxicity was assessed by daily observation, body weight change, hematological and blood chemistry analysis, and histopathology of liver and kidney. The onset of peripheral neurotoxicity was assessed by measuring tail nerve conduction velocity (NCV), morphological and morphometric analysis of dorsal root ganglia (DRG), and morphological analysis of the sciatic nerve. RESULTS Cisplatin induced a statistically significant reduction in body weight, the development of renal failure, and impairment in NCV with pathological alterations in the DRG and sciatic nerve. By contrast, Lipoplatin™ was markedly less nephrotoxic, and no significant weight gain reduction was observed in animals treated with both doses of the drug. Moreover, the lowest dose induced less severe damage to the peripheral nervous system with a moderate decrease in NCV and mild pathological alterations in DRG and the sciatic nerve. CONCLUSIONS The results suggest that Lipoplatin™ 12 mg/kg is less neurotoxic than cisplatin 4 mg/kg, thus opening up the possibility of using this new formulation in future studies where its anticancer activity and the peripheral neurotoxicity will be assessed in parallel.
Collapse
Affiliation(s)
- A Canta
- Department of Neuroscience and Biomedical Technologies, University of Milan Bicocca, Via Cadore 48, 20052, Monza, MB, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Landoni G, Augoustides JG, Guarracino F, Santini F, Ponschab M, Pasero D, Rodseth RN, Biondi-Zoccai G, Silvay G, Salvi L, Camporesi E, Comis M, Conte M, Bevilacqua S, Cabrini L, Cariello C, Caramelli F, De Santis V, Del Sarto P, Dini D, Forti A, Galdieri N, Giordano G, Gottin L, Greco M, Maglioni E, Mantovani L, Manzato A, Meli M, Paternoster G, Pittarello D, Rana NK, Ruggeri L, Salandin V, Sangalli F, Zambon M, Zucchetti M, Bignami E, Alfieri O, Zangrillo A. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference. HSR Proc Intensive Care Cardiovasc Anesth 2011; 3:9-19. [PMID: 23439940 PMCID: PMC3484607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND There is no consensus on which drugs/techniques/strategies can affect mortality in the perioperative period of cardiac surgery. With the aim of identifying these measures, and suggesting measures for prioritized future investigation we performed the first international consensus conference on this topic. METHODS The consensus was a continuous international internet-based process with a final meeting on June 28th 2010 in Milan at the Vita-Salute University. Participants included 340 cardiac anesthesiologists, cardiac surgeons and cardiologists from 65 countries all over the world. A comprehensive literature review was performed to identify topics that subsequently generated position statements for discussion, voting and ranking. RESULTS Of the 17 major topics with a documented mortality effect, seven were subsequently excluded after further evaluation due to concerns about clinical applicability and/or study methodology. The following topics are documented as reducing mortality: administration of insulin, levosimendan, volatile anesthetics, statins, chronic beta-blockade, early aspirin therapy, the use of preoperative intra-aortic balloon counterpulsation and referral to high-volume centers. The following are documented as increasing mortality: administration of aprotinin and aged red blood cell transfusion. These interventions were classified according to the level of evidence and effect on mortality and a position statement was generated. CONCLUSION This international consensus conference has identified the non-surgical interventions that merit urgent study to achieve further reductions in mortality after cardiac surgery: insulin, intra-aortic balloon counterpulsation, levosimendan, volatile anesthetics, statins, chronic beta-blockade, early aspirin therapy, and referral to high-volume centers. The use of aprotinin and aged red blood cells may result in increased mortality.
Collapse
Affiliation(s)
- G Landoni
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - J G Augoustides
- Department of Anesthesiology and Critical Care University of Pennsylvania, Philadelphia, USA
| | - F Guarracino
- Department of Cardiothoracic Anaesthesia and Intensive Care Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - F Santini
- Division of Cardiac Surgery, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - M Ponschab
- Department of Anaesthesia and Intensive Care, Trauma Hospital Linz, Linz, Austria
| | - D Pasero
- Departement of Anesthesia and Critical Care Medicine, San Giovanni Battista Hospital, University of Turin, Italy
| | - R N Rodseth
- Perioperative Research Unit, Department of Anaesthetics, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal & Department of Anaesthetics, Inkosi Albert Luthuli Central Hospital, Durban, South Africa
| | - G Biondi-Zoccai
- Division of Cardiology, University of Modena and Reggio Emilia, Modena, Italy
| | - G Silvay
- Department of Anesthesiology, The Mount of Sinai School of Medicine - New York, USA
| | - L Salvi
- Department of Anaesthesia and ICU, IRCCS Centro Cardiologico Monzino, Milan, Italy
| | - E Camporesi
- Department of Surgery/Anesthesiology; University of South Florida College of Medicine, Tampa, Florida, USA
| | - M Comis
- Department of Anesthesia and Intensive Care, Ospedale Mauriziano Umberto I di Torino, Italy
| | - M Conte
- Department of Anesthesiology and Intensive Care, Città di Lecce Hospital GVM Care & Research, Lecce, Italy
| | - S Bevilacqua
- S.O.D. Cardioanestesia, Dipartimento Cuore e Vasi, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
| | - L Cabrini
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - C Cariello
- Department of Cardiothoracic Anaesthesia and Intensive Care Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - F Caramelli
- Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - V De Santis
- Department of Anesthesiology and Intensive Care, Policlinico Umberto I - Università La Sapienza, Roma, Italy
| | - P Del Sarto
- Department of Anesthesiology and ICU, "G. Monasterio" Tuscan Foundation, "G. Pasquinucci" Heart Hospital, Massa, Italy
| | - D Dini
- S.O.D. Cardioanestesia, Dipartimento Cuore e Vasi, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
| | - A Forti
- Department of Cardiac Surgery, Intensive Care Unit, Regional Hospital Ca' Foncello, Treviso, Italy
| | - N Galdieri
- Department of Anesthesia and Intensive Care, Azienda Ospedaliera Vincenzo Monaldi, Napoli, Italy
| | - G Giordano
- Department of Anesthesiology and Intensive Care, Hesperia Hospital Modena, Modena, Italy
| | - L Gottin
- Department of Anaesthesia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - M Greco
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - E Maglioni
- Department of Anesthsiology and Intensive Care, Policlinico S. Maria alle Scotte, Siena Italy
| | - L Mantovani
- Anestesia e Rianimazione, Ospedali Riuniti di Bergamo, Italy
| | - A Manzato
- Department of Anesthesia and Intensive Care, Pres.Ospedal. Spedali Civili Brescia - Brescia, Italy
| | - M Meli
- Department of Anesthesiology and Intensive Care, Hesperia Hospital Modena, Modena, Italy
| | - G Paternoster
- Departement of Cardiovascular Anaesthesia and Intensive Care Azienda Ospedaliera San Carlo Potenza, Italy
| | - D Pittarello
- Department of Anesthesia and Intensive Care, Azienda Ospedaliera di Padova - Padova, Italy
| | - N K Rana
- Departement of Anesthesia and Critical Care Medicine, San Giovanni Battista Hospital, University of Turin, Italy
| | - L Ruggeri
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - V Salandin
- Department of Cardiac Surgery, Intensive Care Unit, Regional Hospital Ca' Foncello, Treviso, Italy
| | - F Sangalli
- Cardiac Anesthesia and Intensive Care Unit, Department of Perioperative Medicine and Intensive Care, San Gerardo Hospital - University of Milan-Bicocca, Monza, Italy
| | - M Zambon
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - M Zucchetti
- Department of Anesthesia and Intensive Care, Azienda Ospedaliera Papardo, Messina, Italy
| | - E Bignami
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - O Alfieri
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| | - A Zangrillo
- Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy
| |
Collapse
|
37
|
Sala F, Marangon E, Brunelli D, Sessa C, Dall'Ó E, Cereda R, Livi V, D'Incalci M, Zucchetti M. 288 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71995-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
38
|
Landoni G, Bove T, Pasero D, Comis M, Orando S, Pinelli F, Guarracino F, Corcione A, Galdieri N, Zucchetti M, Maglioni E, Biagioli B, Pala G, Frontini M, Caramelli F, Persi B, Renzini M, Paoletti F, Lorini L, Morelli A, Alvaro G, Bianco R, Pittarello D, Manzato A, Pedersini G, Mizzi A, Lojacono N, Leoncini P, Iovino T, Cariello C, Baldassarri R, Camata AM, Padua G, Frascaroli G, Leonardi S, Bignami E, Zangrillo A. Fenoldopam to prevent renal replacement therapy after cardiac surgery. Design of the FENO-HSR study. HSR Proc Intensive Care Cardiovasc Anesth 2010; 2:111-7. [PMID: 23440680 PMCID: PMC3484615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Acute kidney injury requiring renal replacement therapy is a serious complication following cardiac surgery associated with poor clinical outcomes. Until now no drug showed nephroprotective effects. Fenoldopam is a dopamine-1 receptor agonist which seems to be effective in improving postoperative renal function. The aim of this paper is to describe the design of the FENO-HSR study, planned to assess the effect of a continuous infusion of fenoldopam in reducing the need for renal replacement therapy in patients with acute kidney injury after cardiac surgery. METHODS We're performing a double blind, placebo-controlled multicentre randomized trial in over 20 Italian hospitals. Patients who develop acute renal failure defined as R of RIFLE score following cardiac surgery are randomized to receive a 96-hours continuous infusion of either fenoldopam (0.025-0.3 µg/kg/min) or placebo. RESULTS The primary endpoint will be the rate of renal replacement therapy. Secondary endpoints will be: mortality, time on mechanical ventilation, length of intensive care unit and hospital stay, peak serum creatinine and the rate of acute renal failure (following the RIFLE score). CONCLUSIONS This trial is planned to assess if fenoldopam could improve relevant outcomes in patients undergoing cardiac surgery who develop acute renal dysfunction. Results of this double-blind randomized trial could provide important insights to improve the management strategy of patients at high risk for postoperative acute kidney injury.
Collapse
Affiliation(s)
- G Landoni
- Università Vita-Salute San Raffaele, Milano
| | - T Bove
- Università Vita-Salute San Raffaele, Milano
| | - D Pasero
- A.O.U. San Giovanni Battista, Torino
| | - M Comis
- A.O. Ordine Mauriziano, Torino
| | | | | | | | | | | | | | - E Maglioni
- A.O.U. Senese Policlinico S. Maria alle Scotte, Siena
| | - B Biagioli
- A.O.U. Senese Policlinico S. Maria alle Scotte, Siena
| | - G Pala
- Ospedale Civile SS. Annunziata, Sassari
| | | | - F Caramelli
- A.O.U. Policlinico S. Orsola-Malpighi, Bologna
| | - B Persi
- Ospedale Regina S. Maria dei Battuti, Treviso
| | - M Renzini
- A.O. di Perugia - Ospedale S. Maria della Misericordia, Perugia
| | - F Paoletti
- A.O. di Perugia - Ospedale S. Maria della Misericordia, Perugia
| | - L Lorini
- Ospedali Riuniti di Bergamo, Bergamo
| | - A Morelli
- Università La Sapienza - Policlinico Umberto I, Roma
| | - G Alvaro
- A.O. Mater Domini Germaneto, Catanzaro
| | | | | | - A Manzato
- A.O. Spedali Civili di Brescia, Brescia
| | | | - A Mizzi
- Università Vita-Salute San Raffaele, Milano
| | | | | | | | | | | | - A M Camata
- Ospedale Regina S. Maria dei Battuti, Treviso
| | - G Padua
- Ospedale Civile SS. Annunziata, Sassari
| | | | | | - E Bignami
- Università Vita-Salute San Raffaele, Milano
| | | |
Collapse
|
39
|
Marangon E, Sala F, Frapolli R, Manzotti C, Morazzoni P, Pratesi G, Petrangolini G, Tortoreto M, D'Incalci M, Zucchetti M. 180 POSTER The novel taxane derivative, IDN6140, crosses the Blood Brain Barrier and has a promising activity in CNS tumors. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72112-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
40
|
Bartenev S, Ciampichetti A, Firsin N, Forrest R, Kolbasov B, Romanov P, Romanovskij V, Zucchetti M. Activation and clearance of vanadium alloys and beryllium multipliers in fusion reactors. Fusion Engineering and Design 2007. [DOI: 10.1016/j.fusengdes.2007.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007; 97:888-94. [PMID: 17848949 PMCID: PMC2360417 DOI: 10.1038/sj.bjc.6603969] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments. This study examined the antitumour activity of ZD6126, a microtubule destabilising VDA, in combination with paclitaxel (PTX), a microtubule-stabilising cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination. Nude mice bearing MDA-MB-435 xenografts received weekly cycles of ZD6126 (200 mg kg(-1) i.p.) administered at different times before or after PTX (10, 20, and 40 mg kg(-1) i.v.). ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumour necrosis, a hallmark of VDA activity. Paclitaxel counteracting activity was reduced by distancing drug administrations, and ZD6126 given 72 h after PTX potentiated the VDA's antitumour activity. Schedules with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in the viable tumour tissue. Paclitaxel given 72 h after ZD6126 yielded the best response (50% tumours regressing). A single treatment with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions). These findings show that schedule, sequence and timing are crucial in determining the antitumour efficacy of PTX in combination with ZD6126. Induction of tumour necrosis and increased proliferation in the remaining viable tumour tissue could be exploited as readouts to optimise schedules and maximise therapeutic efficacy.
Collapse
Affiliation(s)
- M Martinelli
- Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo 24125, Italy
| | - K Bonezzi
- Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo 24125, Italy
| | - E Riccardi
- Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo 24125, Italy
| | - E Kuhn
- Laboratory of Cancer Pharmacology, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano 20156, Italy
| | - R Frapolli
- Laboratory of Cancer Pharmacology, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano 20156, Italy
| | - M Zucchetti
- Laboratory of Cancer Pharmacology, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano 20156, Italy
| | - A J Ryan
- AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK
| | - G Taraboletti
- Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo 24125, Italy
- E-mail:
| | - R Giavazzi
- Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo 24125, Italy
| |
Collapse
|
42
|
|
43
|
Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 2006; 18:561-8. [PMID: 17150998 DOI: 10.1093/annonc/mdl418] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Gimatecan is an orally bioavailable camptothecin analogue with preclinical findings of promising antitumor activity. A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies. PATIENTS AND METHODS Gimatecan was given daily for five consecutive days per week for 1, 2 or 3 weeks every 28 days. Plasma levels of total gimatecan were measured on the first and the last day of treatment in each schedule. RESULTS Overall, 108 patients were treated with 0.8-7.2 mg/m(2) of gimatecan per cycle. The main toxicity was myelosuppression with dose-limiting thrombocytopenia. In the 1-, 2- and 3-week schedule, the maximum tolerated doses were 4.5, 5.6 and 6.4 mg/m(2). Diarrhea and asthenia were of low grade and of minor clinical relevance, while the higher incidence of nausea and vomiting in the 1-week schedule required the use of antiemetic prophylaxis. Due to the prolonged half-life (approximately 77 h), the plasma concentration of gimatecan increased from the first to the last day of dosing. Six partial responses were observed. CONCLUSIONS Tolerability of gimatecan was schedule dependent. Further testing with schedules taking into account its long persistence in human plasma is worthwhile.
Collapse
Affiliation(s)
- C Sessa
- Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Zucchetti M, Frapolli R, Moliterni A, Mariani P, Locatelli A, Viganò L, Dall'O E, Marsoni S, Pace S, D'Incalci M. 442 POSTER Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70447-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
45
|
Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M. Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors. Drug Metab Dispos 2006; 34:2028-35. [PMID: 16963486 DOI: 10.1124/dmd.106.012153] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III) is a new taxane, derived from 7,8-C-seco-10-deacetylbaccatin, selected for its ability to inhibit angiogenesis, mainly by acting on endothelial cell motility, and for its selective activity on class III beta-tubulin. In vivo, IDN 5390 shows activity against paclitaxel-sensitive and -resistant tumors when administered on a prolonged, continuous dosage schedule. We studied the pharmacokinetics and bioavailabilty of the drug in mice after single and repeated oral treatment. IDN 5390 was rapidly absorbed after oral administration, with good bioavailability (43%). After intravenous injection, it was extensively distributed in tissue, mainly the liver, kidney, and heart, with low but persistent levels in brain. The kinetics appear dose-dependent with a clearance of 2.6, 1.4, and 0.9 l/kg at, respectively, 60, 90, and 120 mg/kg, and a half-life 24, 36, and 54 min. After prolonged daily oral doses given for 2 weeks, we found that there was a decrease in drug availability; i.e., the area under the concentration-time curve value after p.o. daily administration on day 14 was 2-fold lower than that on day 1. Metabolism plays a major role in elimination of the drug, and at least 12 metabolites were identified in feces and urine. The percentage excreted as metabolites after an oral dose (42%) was higher than that after the i.v. dose (33%), suggesting a first-pass effect. Four metabolites were found in plasma at detectable levels; one of them, with restored taxane scaffold, is a species 3 times more potent than IDN 5390, possibly contributing to the observed anti-tumor activity.
Collapse
Affiliation(s)
- R Frapolli
- Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62, 20157 Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, Crucitta E, Marini L, Dal Moro F. Pharmacokinetic Study of Intravesical Gemcitabine in Carcinoma in situ of the Bladder Refractory to Bacillus Calmette-Guérin Therapy. Urol Int 2005; 75:309-13. [PMID: 16327296 DOI: 10.1159/000089164] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2004] [Accepted: 03/23/2005] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Gemcitabine, a chemotherapeutic agent, has been shown to be active against transitional cell cancer of the bladder. The aim of the study was to determine the pharmacokinetic profile of gemcitabine, administered intravesically in patients with carcinoma in situ(CIS). MATERIAL AND METHODS Nine patients with CIS refractory to intravesical bacillus Calmette-Guérin (BCG) therapy were enrolled. Gemcitabine was given in 50 ml 0.9% NaCl by catheterization and held in the bladder for 1 h, once weekly for 6 consecutive weeks. The pharmacokinetics for gemcitabine metabolites were performed in plasma and serum. Dose levels were: 1,000, 1,250, and 1,500 mg. Clinical evaluation was repeated 4 weeks after therapy and thereafter every 6 months. RESULTS Grade-1 neutropenia was observed only in 1 patient. Grade-1 urinary frequency and hematuria were observed in 1 and 3 patients, respectively. No grade 2-4 toxicity or clinically relevant myelosuppression were observed. Gemcitabine was detectable in serum, but with an irrelevant pharmacological effect, in only 1 patient treated with 1,500 mg of gemcitabine. With regard to activity, after 6 instillations of this drug, 4 complete responses were observed. CONCLUSION Intravesical gemcitabine is well tolerated and safe. No systemic absorption with a clinical or pharmacological effect was detected and only slightly irritative bladder symptoms were observed. These results warrant further investigation in phase-II trials.
Collapse
Affiliation(s)
- P Bassi
- Department of Urology, University of Padova Medical School, Padova, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Zaffaroni M, Frapolli R, Riva A, Manzotti C, Morazzoni P, Bombardelli E, D'Incalci M, Zucchetti M. 571 Bioavailability and pharmacokinetic study of the novel oral C-seco taxane derivative IDN 5390 in mice. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80579-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
48
|
Mazzei V, Salamone G, Zucchetti M, Calarco G, Calafiore AM. Ascending aorta aneurysm in an asymptomatic child with cystic medial necrosis and familiar history of aortic disease. J Cardiovasc Surg (Torino) 2004; 45:389-90. [PMID: 15365522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
|
49
|
Caffo O, Santo A, Binato S, Zucchetti M, Lucenti A, Centonze M, Giovannini M, D'Incalci M, Cartei G, Galligioni E. Non conventional suboptimal doses of gemcitabine (G) at fixed dose rate (FDR) infusion, combined with cisplatin (C), in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O. Caffo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - A. Santo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - S. Binato
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - M. Zucchetti
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - A. Lucenti
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - M. Centonze
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - M. Giovannini
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - M. D'Incalci
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - G. Cartei
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| | - E. Galligioni
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Padova, Italy; Mario Negri Institute, Milan, Italy
| |
Collapse
|
50
|
Zaffaroni M, Mucignat C, Pecere T, Zagotto G, Frapolli R, D'Incalci M, Zucchetti M. High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 796:113-9. [PMID: 14552822 DOI: 10.1016/j.jchromb.2003.08.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
An isocratic high-performance liquid chromatography (HPLC) method was developed and validated to determine Aloe Emodin (AE) in mouse plasma. The analysis required 0.3 ml of plasma and involves extraction with dichloromethane. The HPLC separation was carried out on Symmetry Shield RP18, a mobile phase of methanol-water-acetic acid (65:35:0.2) and fluorescence detection at lambda(ex)=410 nm and lambda(em)=510 nm. The retention time of AE was 11.7 min. The assay was linear from 10 to 1,000 ng/ml (r2 > or = 0.999), showed intra- and inter-day precision within 7.8 and 4.7%, and accuracy of 87.3-105.7%. Detection limit (LOD) and quantification limit (LOQ) were 4.5 and 5 ng/ml, respectively. The method was applied to determine for the first time the pharmacokinetic of AE in mice.
Collapse
Affiliation(s)
- M Zaffaroni
- Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|